JP2013515690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013515690A5 JP2013515690A5 JP2012545201A JP2012545201A JP2013515690A5 JP 2013515690 A5 JP2013515690 A5 JP 2013515690A5 JP 2012545201 A JP2012545201 A JP 2012545201A JP 2012545201 A JP2012545201 A JP 2012545201A JP 2013515690 A5 JP2013515690 A5 JP 2013515690A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- chemotherapeutic
- agent
- pharmaceutical
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 11
- 229940127089 cytotoxic agent Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 230000000973 chemotherapeutic effect Effects 0.000 claims 8
- 239000008177 pharmaceutical agent Substances 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 6
- 201000009030 Carcinoma Diseases 0.000 claims 5
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims 5
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 4
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 239000012625 DNA intercalator Substances 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 229940127093 camptothecin Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 239000000138 intercalating agent Substances 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006143 Brain stem glioma Diseases 0.000 claims 1
- 201000009047 Chordoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010024305 Leukaemia monocytic Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010050487 Pinealoblastoma Diseases 0.000 claims 1
- 208000007641 Pinealoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 claims 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 claims 1
- 239000003124 biologic agent Substances 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 208000002458 carcinoid tumor Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- -1 ethoxy imino methyl camptothecin Chemical compound 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 201000003115 germ cell cancer Diseases 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000011061 large intestine cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000003593 megakaryocyte Anatomy 0.000 claims 1
- 201000006894 monocytic leukemia Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 1
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 1
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical group N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 1
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims 1
- 229960000572 olaparib Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 208000029211 papillomatosis Diseases 0.000 claims 1
- RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical compound C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 claims 1
- 201000003113 pineoblastoma Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000003804 salivary gland carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046885 vaginal cancer Diseases 0.000 claims 1
- 208000013139 vaginal neoplasm Diseases 0.000 claims 1
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 claims 1
- 229950011257 veliparib Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180666.1 | 2009-12-23 | ||
| EP09180666 | 2009-12-23 | ||
| PCT/EP2010/068924 WO2011076547A1 (en) | 2009-12-23 | 2010-12-06 | Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013515690A JP2013515690A (ja) | 2013-05-09 |
| JP2013515690A5 true JP2013515690A5 (enExample) | 2015-05-21 |
Family
ID=41647059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012545201A Ceased JP2013515690A (ja) | 2009-12-23 | 2010-12-06 | アルテミシニンベースの薬剤と他の化学療法薬の抗癌用組合せ |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9023861B2 (enExample) |
| EP (1) | EP2515898A1 (enExample) |
| JP (1) | JP2013515690A (enExample) |
| KR (1) | KR20120096053A (enExample) |
| CN (1) | CN102665711A (enExample) |
| AR (1) | AR079654A1 (enExample) |
| AU (1) | AU2010335422A1 (enExample) |
| BR (1) | BR112012015606A2 (enExample) |
| CA (1) | CA2780591A1 (enExample) |
| EA (1) | EA201200934A1 (enExample) |
| IL (1) | IL220561A0 (enExample) |
| IN (1) | IN2012DN03914A (enExample) |
| MX (1) | MX2012006738A (enExample) |
| MY (1) | MY157475A (enExample) |
| NZ (1) | NZ599878A (enExample) |
| PH (1) | PH12012500893A1 (enExample) |
| SG (1) | SG10201408485SA (enExample) |
| TW (1) | TWI482621B (enExample) |
| UA (1) | UA107691C2 (enExample) |
| WO (1) | WO2011076547A1 (enExample) |
| ZA (1) | ZA201205360B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| US9801851B2 (en) * | 2012-05-23 | 2017-10-31 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias |
| US20170049815A1 (en) * | 2014-05-02 | 2017-02-23 | Emory University | Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto |
| US9918972B2 (en) * | 2014-12-23 | 2018-03-20 | The University Of Maryland, Baltimore | Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents |
| CN105963262B (zh) * | 2016-06-06 | 2018-11-30 | 北京林业大学 | 一种两亲性果胶-双氢青蒿素纳米粒子的制备方法 |
| CN110051849A (zh) * | 2016-08-26 | 2019-07-26 | 宁国市厚普生物科技有限公司 | 一种复合物在制备用于治疗乳腺癌的药物中的应用 |
| CN109453156A (zh) * | 2018-11-22 | 2019-03-12 | 中国中医科学院中药研究所 | 一种抗肿瘤组合物及其应用、抗肿瘤药物 |
| EP3868372A1 (en) * | 2020-02-19 | 2021-08-25 | JLP Health GmbH | A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer |
| CN114053276B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 |
| CN114053271B (zh) * | 2020-07-30 | 2024-05-07 | 江苏天士力帝益药业有限公司 | 一种含有tsl-1502m的药物组合物及其应用 |
| CN114010643A (zh) * | 2021-11-23 | 2022-02-08 | 温州医科大学 | 双氢青蒿素在抗肿瘤药物的制备中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578637A (en) | 1995-05-03 | 1996-11-26 | University Of Washington | Methods of inhibition or killing cancer cells using an endoperoxide |
| EP1044977B1 (en) | 1999-03-09 | 2002-05-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. | Camptothecin derivatives having antitumor activity |
| KR100390332B1 (ko) | 2000-08-02 | 2003-07-07 | 유원민 | 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물 |
| ATE485039T1 (de) * | 2003-02-12 | 2010-11-15 | Univ Georgetown | Verwendung von artemisinin zur behandlung von durch onkogene viren gebildeten tumoren und zur behandlung von viralen infektionen |
| EP1658844A1 (en) | 2004-10-19 | 2006-05-24 | Gerold Schuler | Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US8143284B2 (en) * | 2006-10-05 | 2012-03-27 | Abbott Laboratories | Poly(ADP-ribose)polymerase inhibitors |
| CN101784268B (zh) | 2006-11-20 | 2013-06-19 | 赛福伦公司 | 使用辐射敏化剂使肿瘤对辐射敏化的方法 |
| CN101125140B (zh) * | 2007-09-18 | 2011-04-13 | 浙江大学 | 二氢青蒿素在制备增强化疗药物抗肿瘤疗效的药物中的应用 |
| WO2009114459A2 (en) * | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| CN101380325A (zh) * | 2008-10-23 | 2009-03-11 | 上海交通大学 | 青蒿素衍生物与长春瑞滨的组合物及其应用 |
| CN101428034B (zh) * | 2008-12-12 | 2012-02-08 | 广州市允中投资发展有限公司 | 具有增效减毒特点的抗肿瘤组合药物 |
| CN101856352A (zh) * | 2009-04-10 | 2010-10-13 | 中国科学院上海生命科学研究院 | 青蒿素及其衍生物对化疗剂的协同作用 |
-
2010
- 2010-11-22 TW TW099140203A patent/TWI482621B/zh not_active IP Right Cessation
- 2010-12-06 JP JP2012545201A patent/JP2013515690A/ja not_active Ceased
- 2010-12-06 CN CN2010800580524A patent/CN102665711A/zh active Pending
- 2010-12-06 BR BR112012015606A patent/BR112012015606A2/pt not_active IP Right Cessation
- 2010-12-06 MY MYPI2012001992A patent/MY157475A/en unknown
- 2010-12-06 NZ NZ599878A patent/NZ599878A/en not_active IP Right Cessation
- 2010-12-06 MX MX2012006738A patent/MX2012006738A/es not_active Application Discontinuation
- 2010-12-06 KR KR1020127016599A patent/KR20120096053A/ko not_active Withdrawn
- 2010-12-06 SG SG10201408485SA patent/SG10201408485SA/en unknown
- 2010-12-06 IN IN3914DEN2012 patent/IN2012DN03914A/en unknown
- 2010-12-06 UA UAA201208932A patent/UA107691C2/ru unknown
- 2010-12-06 PH PH1/2012/500893A patent/PH12012500893A1/en unknown
- 2010-12-06 EA EA201200934A patent/EA201200934A1/ru unknown
- 2010-12-06 EP EP10788312A patent/EP2515898A1/en not_active Withdrawn
- 2010-12-06 AU AU2010335422A patent/AU2010335422A1/en not_active Abandoned
- 2010-12-06 WO PCT/EP2010/068924 patent/WO2011076547A1/en not_active Ceased
- 2010-12-06 CA CA2780591A patent/CA2780591A1/en not_active Abandoned
- 2010-12-06 US US13/518,185 patent/US9023861B2/en not_active Expired - Fee Related
- 2010-12-21 AR ARP100104807A patent/AR079654A1/es unknown
-
2012
- 2012-06-21 IL IL220561A patent/IL220561A0/en unknown
- 2012-07-18 ZA ZA2012/05360A patent/ZA201205360B/en unknown